PMID- 29067094
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 14
IP  - 5
DP  - 2017 Nov
TI  - Dasatinib and chemotherapy in a patient with early T-cell precursor acute 
      lymphoblastic leukemia and NUP214-ABL1 fusion: A case report.
PG  - 3979-3984
LID - 10.3892/etm.2017.5046 [doi]
AB  - The present study aimed to evaluate the therapeutic efficacy of dasatinib in a 
      patient with nucleoporin 214-tyrosine protein kinase ABL1 proto-oncogene 1 
      (NUP214-ABL1)-positive early T-cell precursor-acute lymphoblastic leukemia 
      (ETP-ALL), as well as that of selinexor and dasatinib for NUP214-ABL1-positive 
      ETP-ALL in vitro. ETP leukemia is a form of T-cell ALL (T-ALL) with poor 
      prognosis. The NUP214-ABL1 gene is present in ~6% of T-ALL cases, however the 
      prevalence of NUP214-ABL1 gene expression in ETP-ALL in particular has not yet 
      been verified. The current study reports the rare case of a 29-year-old man with 
      ETP-ALL harboring the NUP214-ABL1 fusion gene, presenting with low-grade fever, 
      stomachache and splenomegaly. The patient was successfully treated with dasatinib 
      and vincristine, idarubicin, cyclophosphamide and prednisone (VICP) chemotherapy. 
      The therapeutic efficacy of selinexor and dasatinib was also evaluated in vitro. 
      Apoptosis was analyzed using Annexin V/propidium iodide staining and flow 
      cytometry, and poly ADP-ribose polymerase (PARP) cleavage was detected using 
      western blot analysis. The results demonstrated that the apoptotic cell 
      population significantly increased following selinexor or dasatinib treatment 
      compared with the control (P<0.05). Furthermore, combined selinexor and dasatinib 
      treatment led to a significant increase in cell apoptosis compared with either 
      treatment alone (P<0.05). The apoptosis results were confirmed by PARP cleavage. 
      Thus, NUP214-ABL1 fusion gene expression should be tested in T-ALL, including 
      ETP-ALL. Dasatinib used in combination with traditional induction chemotherapy 
      may reverse the high induction failure of ETP-ALL with NUP214-ABL1 fusion gene; 
      however, further prospective studies are required to confirm this. Therefore, 
      selinexor with or without dasatinib may serve as a potential salvage therapy in 
      the case of relapse and may be developed as a novel treatment for ETP-ALL with 
      the NUP214-ABL1 fusion gene.
FAU - Chen, Yan
AU  - Chen Y
AD  - Department of Hematology, Zhongshan Hospital, Xiamen University, Xiamen, Fujian 
      361004, P.R. China.
FAU - Zhang, Li
AU  - Zhang L
AD  - Department of Hematology, West China Hospital, Sichuan University, Chengdu, 
      Sichuan 610041, P.R. China.
FAU - Huang, Jiankun
AU  - Huang J
AD  - Central Laboratory, Zhongshan Hospital, Xiamen University, Xiamen, Fujian 361004, 
      P.R. China.
FAU - Hong, Xiuli
AU  - Hong X
AD  - Department of Hematology, Zhongshan Hospital, Xiamen University, Xiamen, Fujian 
      361004, P.R. China.
FAU - Zhao, Jiangning
AU  - Zhao J
AD  - Department of Hematology, Zhongshan Hospital, Xiamen University, Xiamen, Fujian 
      361004, P.R. China.
FAU - Wang, Zhao
AU  - Wang Z
AD  - Department of Hematology, Zhongshan Hospital, Xiamen University, Xiamen, Fujian 
      361004, P.R. China.
FAU - Zhang, Kejie
AU  - Zhang K
AD  - Department of Hematology, Zhongshan Hospital, Xiamen University, Xiamen, Fujian 
      361004, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20170828
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC5647690
OTO - NOTNLM
OT  - NUP214-ABL1
OT  - T-cell
OT  - dasatinib
OT  - early T-cell precursor acute lymphoblastic leukemia
OT  - selinexor
EDAT- 2017/10/27 06:00
MHDA- 2017/10/27 06:01
PMCR- 2017/08/28
CRDT- 2017/10/26 06:00
PHST- 2016/02/26 00:00 [received]
PHST- 2017/03/23 00:00 [accepted]
PHST- 2017/10/26 06:00 [entrez]
PHST- 2017/10/27 06:00 [pubmed]
PHST- 2017/10/27 06:01 [medline]
PHST- 2017/08/28 00:00 [pmc-release]
AID - ETM-0-0-5046 [pii]
AID - 10.3892/etm.2017.5046 [doi]
PST - ppublish
SO  - Exp Ther Med. 2017 Nov;14(5):3979-3984. doi: 10.3892/etm.2017.5046. Epub 2017 Aug 
      28.